Treatment of somatoform disorders in patients with COPD, as well as treatment of COPD in patients with somatic disorders, is relevant and should be carried out in accordance with international recommendations. The choice of antidepressant should be safe and effective even with complex comorbidity patterns. This will allow using a pathogenetic approach to provide assistance to these patients. Paroxetine is the most effective and safe antidepressant group of selective serotonin reuptake inhibitors.
The aim of the work was to conduct a comprehensive assessment of the effects of paroxetine on the level of somatoform disorders during exacerbation of severe COPD (grup D) in women. The study included 53 patients with severe COPD, which was confirmed by instrumental research methods. The patients were divided into 2 groups. Patients of the first group (n=21) — (52.5±0.8) years old were prescribed basic exacerbation therapy. Patients of the second group (n=22) — (57.9±0.4) years old, in addition to the basic therapy of exacerbation, was prescribed paroxetine for 14 days, 1 tablet (0.20 g) 1 time per day. During the analysis of the COPD exacerbations treatment results with the basic treatment and paroxetine showed that the clinical effect was obtained in both groups. But, the severity of the treatment of exacerbation was observed in patients who additionally received paroxetine. The initial values of the indicators in the comparison groups were identical, and upon completion of inpatient treatment, a more pronounced improvement was achieved in patients who were prescribed combination therapy. When synchronizing the standard therapy of somatoform disorders in patients with acute exacerbation of severe COPD, an effect on a cascade of pathological lesions was noted. The results of the conducted studies allow us to recommend paroxetine taking as an addition to basic therapy to slow the progression of the somatoform disorders.